Prescribing & Dispensing algorithm for PROPHYLAXIS with oseltamivir (TAMIFLU)

Close contact with an infected individual and within 2 days of exposure?
- No → Not indicated
- Yes → Known hypersensitivity to any components of the product?
  - No → Not indicated
  - Yes → Refer

Known hypersensitivity to any components of the product?
- Yes → Refer
- No → Live attenuated influenza vaccine administered within prior 2 weeks (nasal-spray flu vaccine)
  - Yes → Refer
  - No → Age 13 years and older?
    - No → Child < 1 year of age?
      - Yes → Dispense oral suspension (refer to Table 2 below)
      - No → Dispense oral suspension or capsules (refer to Table 1 below)
    - Yes → Renal dysfunction
      - Yes → Dispense oseltamivir 75mg every other day OR 30mg once daily for 10 days
      - No → For CrCl 10-30mL/min: Dispense oseltamivir 75mg every other day OR 30mg once daily for 10 days
      - For HD: dispense oseltamivir 30mg twice weekly
      - For CAPD: dispense oseltamivir 30mg once weekly
  
Nursing mother?
- Yes → Pregnancy category C; use only if the potential benefit justifies the potential risk to the fetus
- No → Child < 1 year of age
  - Yes → Dispense oral suspension (refer to Table 2 below)
  - No → Dispense oral suspension or capsules (refer to Table 1 below)

Parenteral products are not recommended in patients with Child < 1 year of age, and the benefit of treatment should be weighed against the potential risk to the breastfed infant.
**Prophylaxis in pediatric patients 1 year and older** (oral suspension or capsules)

<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>Body weight (lbs)</th>
<th>Recommended dose for 10 days</th>
<th>Number of bottles needed to obtain recommended dose for a 10 day regimen</th>
<th>Number of capsules needed to obtain recommended doses for a 10 day regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 15</td>
<td>≤ 33</td>
<td>30mg once daily</td>
<td>1</td>
<td>10 x 30mg capsules</td>
</tr>
<tr>
<td>&gt;15-23</td>
<td>&gt;33-51</td>
<td>45mg once daily</td>
<td>2</td>
<td>10 x 45mg capsules</td>
</tr>
<tr>
<td>&gt;23-40</td>
<td>&gt;51-88</td>
<td>60mg once daily</td>
<td>2</td>
<td>20 x 30mg capsules</td>
</tr>
<tr>
<td>&gt;40</td>
<td>&gt;88</td>
<td>75 mg once daily</td>
<td>3</td>
<td>10 x 75mg capsules</td>
</tr>
</tbody>
</table>

**Table 2**

**Prophylaxis for children younger than 1 year***

<table>
<thead>
<tr>
<th>Age</th>
<th>Recommended prophylaxis dose for 10 days</th>
<th>Number of bottles needed to obtain recommended dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 3 months</td>
<td>Not recommended unless situation judged critical due to limited data on use in this age group</td>
<td></td>
</tr>
<tr>
<td>3-5 months</td>
<td>20mg once daily</td>
<td>1</td>
</tr>
<tr>
<td>6-11 months</td>
<td>25mg once daily</td>
<td>1</td>
</tr>
</tbody>
</table>

* Under the emergency use authorization (EUA) issued by the United States Food and Drug Administration (FDA), oseltamivir (Tamiflu) may also be used to treat and prevent influenza in children under 1 year (issued 4/27/09)

1. No adverse effects have been reported among women who received oseltamivir during pregnancy or among infants born to women who have received oseltamivir. Pregnancy should NOT be considered a contraindication to oseltamivir use.